ALBERT MAHLER MAGUIRE
Medical Practice in Delaware
License number
Pennsylvania MD046589L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Delaware
Rosemont, PA 19010
Rosemont, PA 19010
Personal information
See more information about ALBERT MAHLER MAGUIRE at radaris.comName
Address
Phone
182 Fishers Rd, Bryn Mawr, PA 19010
3400 Spruce St, Philadelphia, PA 19104
182 Fishers Rd, Bryn Mawr, PA 19010
39 Market St, Philadelphia, PA 19106
Professional information
Method Of Treating Or Retarding The Development Of Blindness
US Patent:
2013021, Aug 22, 2013
Filed:
Feb 13, 2013
Appl. No.:
13/766267
Inventors:
The Trustees of the University of Pennsylvania - , US
University of Florida Research Foundation, Incorporated - , US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
University of Florida Research Foundation, Incorporated - , US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
Cornell Research Foundation, Inc. - Ithaca NY
University of Florida Research Foundation, Incorporated - Gainesville FL
Cornell Research Foundation, Inc. - Ithaca NY
University of Florida Research Foundation, Incorporated - Gainesville FL
International Classification:
A61K 38/52, C12N 15/864
US Classification:
424 932, 4353201
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Method Of Treating Or Retarding The Development Of Blindness
US Patent:
2010027, Oct 28, 2010
Filed:
Jul 8, 2010
Appl. No.:
12/832282
Inventors:
Gregory M. Acland - Kennett Square PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
University of Florida Research Foundation, Incorporated - Gainesville FL
Cornell Research Fountaintion, Inc. - Ithaca NY
University of Florida Research Foundation, Incorporated - Gainesville FL
Cornell Research Fountaintion, Inc. - Ithaca NY
International Classification:
A61K 48/00, A61P 27/02
US Classification:
424 932
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Method Of Treating Or Retarding The Development Of Blindness
US Patent:
2009007, Mar 19, 2009
Filed:
Oct 18, 2008
Appl. No.:
12/253955
Inventors:
Gregory M. Acland - Kennett Square PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
The University of Florida Research Foundation, Inc. - Gainesville FL
Cornell Research Foundation, Inc. - Ithaca NY
The University of Florida Research Foundation, Inc. - Gainesville FL
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
A61K 48/00, A61K 31/7088, A61K 35/12, A61K 35/76, A61P 27/02
US Classification:
424 932, 514 44
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Method Of Treating Or Retarding The Development Of Blindness
US Patent:
2007007, Apr 5, 2007
Filed:
Aug 28, 2006
Appl. No.:
11/511201
Inventors:
Gregory Acland - Kennett Square PA, US
Gustavo Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William Hauswirth - Gainesville FL, US
Samuel Jacobson - Penn Valley PA, US
Albert Maguire - Bryn Mawr PA, US
Gustavo Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William Hauswirth - Gainesville FL, US
Samuel Jacobson - Penn Valley PA, US
Albert Maguire - Bryn Mawr PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
The University of Florida Research Foundation, Inc - Gainesville FL
Cornell Research Foundation, Inc. - Ithaca NY
The University of Florida Research Foundation, Inc - Gainesville FL
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
A61K 48/00
US Classification:
424093200, 514044000
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Method Of Treating Or Retarding The Development Of Blindness
US Patent:
2004002, Feb 5, 2004
Filed:
Nov 20, 2002
Appl. No.:
10/300720
Inventors:
Gregory Acland - Kennett Square PA, US
Gustayo Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William Hauswirth - Gainesville FL, US
Samuel Jacobson - Penn Valley PA, US
Albert Maguire - Bryn Mawr PA, US
Gustayo Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William Hauswirth - Gainesville FL, US
Samuel Jacobson - Penn Valley PA, US
Albert Maguire - Bryn Mawr PA, US
International Classification:
A61K048/00
US Classification:
424/093200
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Method Of Treating Or Retarding The Development Of Blindness
US Patent:
2012022, Sep 6, 2012
Filed:
Feb 28, 2012
Appl. No.:
13/406666
Inventors:
Gregory M. Acland - Kennett Square PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
International Classification:
A61K 31/711, A61P 27/02
US Classification:
514 44 R
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.